Note: AI-generated summary based on third-party content. Not financial advice. Read more.
Quick Insights
Consider a diversified semiconductor investment for exposure to AI growth; the outlook is cautiously bullish, but avoid relying on NVIDIA (NVDA) alone because more efficient models and future technologies could pressure chip demand.
Meta Platforms (META) is a higher-conviction AI-product idea, with its distribution and product capabilities potentially helping it turn AI into services; no price target or timeframe was provided.
Treat photonic computing as a long-term theme, not a near-term trade: the discussion suggested a roughly 20-year horizon and named no investable companies.
Detailed Analysis
NVIDIA (NVDA)
Shkreli said he is long semiconductors, while cautioning that NVIDIA could face pressure if AI models become much more efficient.
He cited the possibility of transformers becoming 1,000 times more efficient as a reason demand for NVIDIA’s chips could be lower than expected.
He expects today’s H100, B100, and B200 chips to become obsolete over time, and said photonic computing could eventually offer a better approach.
He also argued that demand for compute may keep growing because businesses have substantial demand for intelligence and work. However, he questioned whether compute needs could grow by a million times.
Takeaways
The discussion presents a mixed outlook for NVIDIA: growing AI use could support chip demand, but more efficient models or new computing technologies could reduce the amount of hardware needed.
For investors, the key issue raised is whether efficiency gains will be outweighed by new uses for AI. Shkreli did not give a price target or a specific holding period.
Semiconductor Sector
Shkreli said he is long semiconductors and expressed a generally positive view of the sector’s role in the AI buildout.
He also warned that picking the lasting winners is difficult, comparing the challenge to investors in 2000 who might have assumed Yahoo and Cisco would remain winners.
He described the current investment outlook as uncertain, despite his long position.
Takeaways
The transcript supports a cautiously bullish but uncertain view of semiconductors: AI demand may create opportunities, but today’s leaders may not capture the benefits indefinitely.
The risk highlighted is winner selection—investors may be right about AI growth but wrong about which companies ultimately earn the most from it.
Photonic Computing
Shkreli said photonic computing could be a better way to perform computing in the future and suggested that today’s GPU generations could eventually be replaced.
He referred to a 20-year horizon for the idea and noted that Sam Altman had publicly described photonic computing as a potential future technology.
Takeaways
Photonic computing is presented as a long-term technology theme, not a near-term investment recommendation.
No specific companies or securities were named, and the transcript gives no details on commercialization timing beyond Shkreli’s broad 20-year framing.
Meta Platforms (META)
Shkreli described the timing as favorable for Meta, pointing to its distribution and product capabilities.
He cited Meta’s Muse product work as evidence that the company may be able to create new AI-enabled products.
He also praised Meta for publicly pushing back against what he views as exaggerated fears about AI.
Takeaways
Shkreli’s comments were bullish on Meta’s ability to turn AI into products, particularly by using its existing distribution.
The transcript does not include a price target, valuation analysis, or specific recommendation to buy Meta shares.
OpenAI and Anthropic
When asked whether he would buy OpenAI and Anthropic, Shkreli said yes.
He argued that AI opportunities could extend beyond knowledge work and that AI firms might eventually build businesses across sectors such as pharmaceuticals, motors, and aviation.
He also said Sam Altman’s move toward hardware could help OpenAI deliver its models, not just develop them.
Separately, he said the AI market may resemble the internet: consumers and businesses could capture much of the benefit, while only some technology providers earn substantial returns.
Takeaways
Shkreli expressed a bullish view of AI’s long-term potential, but also suggested that broad economic benefits do not guarantee that AI providers will be the biggest financial winners.
OpenAI and Anthropic are not publicly traded companies, and the transcript does not identify a specific public security or investment vehicle.
Core Automation
Shkreli said he was excited about Core Automation, a startup founded by a former OpenAI employee whom he described as having invented OpenAI’s reasoning model.
He linked the company to the broader idea that AI could start and operate businesses across multiple industries.
Takeaways
Core Automation is a private startup opportunity mentioned favorably, but the transcript provides no financial details, valuation, or way for the general public to invest.
The idea is speculative: the discussion describes a potential business model, not evidence that it has been proven at scale.
AI in Drug Discovery
Shkreli strongly disputed claims that AI would quickly transform drug discovery. He said he did not expect an AI-relevant drug in the next 10 years and argued that computing tools have not removed the difficulty of developing drugs.
He acknowledged that GPUs can help with analysis but said he sees limited help from AI in drug discovery.
He also criticized claims that AI would cure diseases, treating those claims as excessive or unsubstantiated.
Takeaways
Shkreli’s view on AI-enabled drug discovery was bearish and skeptical, especially regarding near-term expectations.
The transcript names no pharmaceutical stock or specific drug-development investment. His comments are a caution against assuming that AI adoption will quickly translate into successful medicines.
AI Investment Theme
Shkreli argued that demand for intelligence and work could be very large, including from businesses willing to spend heavily on AI if it improves decisions or productivity.
He said he does not see the AI valuation environment as necessarily a “valuation trap,” but acknowledged uncertainty about how long individual companies can earn outsized returns.
He called the recent market sell-off “ridiculous,” though no specific security or index was identified.
Takeaways
The discussion is bullish on the potential size of the AI market, but more cautious about identifying which companies will capture the value.
The practical distinction raised is between AI adoption and investment returns: broad usage may benefit consumers and businesses without guaranteeing lasting profits for every AI provider.
Ask about this postAnswers are grounded in this post's content.
Video Description
I explain why I disagree with Dario Amodei's outlook on AI, where I see the investment opportunities, and why I'm optimistic about AI's commercial potential.
We discuss NVIDIA, the future of computing, effective altruism, AI drug discovery, and whether demand for intelligence has a limit. I also share my views on Meta, OpenAI, AI safety, and how AI could create entire businesses.
From my interview at the All-In Summit.
Watch the original interview on The All-In Podcast:
https://www.youtube.com/watch?v=yZR8QW4qQmM
00:00 NVIDIA and future AI computing
01:34 My portfolio approach
02:07 Dario Amodei and AI pessimism
03:31 Effective altruism vs. accelerationism
04:55 My view on AI drug discovery
05:24 Demand for intelligence and AI-created companies
07:16 Who wins in the AI market?
08:58 AI safety and competitor peer review
Join me on Godel Terminal:
https://app.godelterminal.com/?page=register&via=BIG
Godel Terminal:
https://godelterminal.com
LINKS:
X: https://x.com/martinshkreli
GitHub: https://github.com/martinshkreli
Discord: https://discord.com/invite/martinshkreli
TikTok: https://www.tiktok.com/@martinshkreli15
Instagram: https://www.instagram.com/martinshkreli15/
LinkTree: https://linktr.ee/martinshkreli